EXEL
NASDAQ · Biotechnology
Exelixis Inc
$54.07
+1.87 (+3.58%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
+23.03%
1Y
+43.35%
YTD
+24.07%
Open$52.69
Previous Close$52.20
Day High$54.14
Day Low$52.17
52W High$57.57
52W Low$33.76
Volume—
Avg Volume3.07M
Market Cap13.19B
P/E Ratio15.83
EPS$3.02
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$43.59
Above
SMA 200
$41.49
Above
RSI (14)
62
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Hold
25 analysts
Price Target
+114.7% upside
Current
$54.07
$54.07
Target
$116.10
$116.10
$78.53
$116.10 avg
$123.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.01B | 1.78B | 2.68B |
| Net Income | 677.51M | 539.94M | -77,688,294 |
| Profit Margin | 33.7% | 32.0% | -2.9% |
| EBITDA | 780.27M | 656.38M | -84,355,918 |
| Free Cash Flow | — | — | -70,301,392 |
| Rev Growth | +12.9% | +12.9% | +9.9% |
| Debt/Equity | — | — | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |